John Fetterman gives us a chance to banish eugenic ideas of fitness
By Jaipreet Virdi,
The Washington Post
| 11. 04. 2022
Photo by visuals on Unsplash
Democrat John Fetterman’s performance in Pennsylvania’s lone Senate debate provoked intense discussions about his fitness for office while recovering from a stroke. Fetterman’s verbal stumbles and pauses intensified Republican accusations that his health is too frail to withstand the job of a senator, even as doctors and disability advocates pushed back on these charges. But while some saw Fetterman’s halting speech and need for closed captioning as evidence of cognitive impairment, the conversation surrounding his fitness is premised on bias and ableism. The polished, articulate and groomed image we associate with the ideal politician means that anyone who does not meet this ideal is considered subpar — and hence “unfit.” But that understanding of what makes someone capable of holding office is actually rooted in eugenics.
In 1883, British polymath Sir Francis Galton first developed eugenics as a science for improving the inborn qualities of the human race. Eugenics swept into American society around the turn of the 20th century as a Progressive solution for addressing widespread problems caused by groups deemed “socially inadequate.” As...
Related Articles
By Vittoria Vardanega, SWI swissinfo.ch | 02.13.2026
In recent years, sperm donation has produced family trees of unprecedented size, stretching across countries and, in some cases, continents. Stories of “mass donors” have captured public attention, most recently through the Netflix documentary series, The Man with 1,000 Kids...
By Jonathan D. Moreno, Hastings Center Bioethics Forum | 02.09.2026
When I began to write a book about bioethics and the rules-based international order, the idea that the world was facing the greatest geopolitical change since World War II was uncontroversial for those who were paying attention to such esoterica...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...